MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Corium International Company Profile (NASDAQ:CORI)

Consensus Ratings for Corium International (NASDAQ:CORI) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $13.00 (220.20% upside)

Analysts' Ratings History for Corium International (NASDAQ:CORI)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Needham & Company LLCReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Leerink SwannReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Jefferies GroupReiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016WBB SecuritiesUpgradeHold -> Speculative Buy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Corium International (NASDAQ:CORI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/27/2016        
5/10/2016Q2($0.37)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2016Q1($0.35)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q4($0.45)($0.42)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2015Q115($0.24)($0.37)$10.42 million$9.77 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2014($0.32)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.17)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014($0.18)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Corium International (NASDAQ:CORI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.38)($0.38)($0.38)
Q2 20161($0.35)($0.35)($0.35)
Q3 20163($0.43)($0.41)($0.42)
Q4 20163($0.41)($0.38)($0.39)
(Data provided by Zacks Investment Research)
Dividend History for Corium International (NASDAQ:CORI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Corium International (NASDAQ:CORI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/19/2016Eric BjerkholtDirectorBuy24,500$3.64$89,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016David GreenwoodDirectorBuy3,000$3.58$10,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Peter D StapleCEOBuy3,600$6.99$25,164.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Robert S BreuilCFOBuy4,600$5.38$24,748.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Peter D StapleCEOBuy9,000$5.34$48,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Peter D StapleCEOBuy2,578$6.10$15,725.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/30/2014Peter D StapleCEOBuy7,200$7.04$50,688.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014Woodlands Health Venture EssexMajor ShareholderBuy400,000$8.00$3,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Corium International (NASDAQ:CORI)
DateHeadline
06/23/16 09:40 AMImpetigo Pipeline H1 2016 Reviewed for Global Markets
06/20/16 01:15 PMETF’s with exposure to Corium International, Inc. : June 20, 2016 -
06/16/16 08:39 PMCORIUM INTERNATIONAL, INC. : Costs Associated with Exit or Disposal Activities (form 8-K)
06/15/16 04:05 PMCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities -
06/07/16 10:08 AMCorium International, Inc. :CORI-US: Earnings Analysis: Q2, 2016 By the Numbers : June 7, 2016 -
06/04/16 11:51 AMGlobal Obesity Pipeline Report H1 2016 - Review of 98 Companies & Drug Profiles - Research and Markets
05/25/16 03:26 PMCorium to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - MENLO PARK, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization ...
05/13/16 03:08 PMCORIUM INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report -
05/12/16 06:55 AMEdited Transcript of CORI earnings conference call or presentation 10-May-16 9:00pm GMT -
05/10/16 05:06 PMCorium reports 2Q loss -
05/10/16 03:28 PMCorium Reports Second Quarter Fiscal 2016 Financial Results and Recent Corporate Highlights - [at noodls] - MENLO PARK, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization ...
05/10/16 06:07 AMQ2 2016 Corium International Inc Earnings Release - After Market Close -
05/04/16 07:15 AMCorium International (CORI) Jumps: Stock Moves 9.5% Higher -
05/03/16 03:20 PMCorium to Report Second Quarter Fiscal Year 2016 Financial Results on Tuesday, May 10, 2016 - [at noodls] - MENLO PARK, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the second fiscal quarter ended March 31, 2016 on ...
05/03/16 07:41 AMCorium International upgraded by WBB Securities -
04/14/16 02:00 PMETF’s with exposure to Corium International, Inc. : April 14, 2016 -
04/06/16 10:58 AMCorium International, Inc. :CORI-US: Earnings Analysis: Q1, 2016 By the Numbers -
03/31/16 07:09 AMCorium to Present at 15th Annual Needham Healthcare Conference - [at noodls] - MENLO PARK, Calif., March 31, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization ...
03/29/16 03:13 PMCorium Announces Positive Preclinical Results with Long-acting Potent GLP-1 Analog Delivered in MicroCor® Transdermal Patch - [at noodls] - MENLO PARK, Calif., March 29, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization ...
03/19/16 01:06 PMAnalysts Expect UWM Will Reach $84 - Three of UWM's underlying holdings with notable upside to their analyst target prices are Corium International Inc (CORI), Ardelyx Inc (ARDX), and Adamas Pharmaceuticals Inc (ADMS). Although CORI has traded at a recent price of $4.23/share, the average ...
03/09/16 03:07 PMCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
02/23/16 07:15 AMCorium International (CORI) in Focus: Stock Moves Up 8.5% -
02/22/16 03:03 PMCorium Announces Positive Topline Results From Phase 1 Clinical Study of Transdermal Corplex™ Memantine as a Potential Treatment of Alzheimer’s Disease - [GlobeNewswire] - Demonstrates Pharmacokinetic Profile Supporting the Feasibility of Sustained Transdermal Delivery. Webcast and Conference Call Today at 5:00 p.m. ET. MENLO PARK, Calif., Feb. 22, 2016-- Corium International, ...
02/12/16 03:38 PMCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
02/08/16 03:14 PMCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an -
02/08/16 03:14 PMCorium reports 1Q loss -
02/08/16 03:03 PMCorium Reports First Quarter Fiscal 2016 Financial Results - [GlobeNewswire] - MENLO PARK, Calif., Feb. 08, 2016-- Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, ...
02/08/16 06:07 AMQ1 2016 Corium International Inc Earnings Release - After Market Close -
02/05/16 07:15 AMCorium International (CORI) Jumps: Stock Moves Up 8.9% -
02/03/16 03:10 PMCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
02/03/16 03:04 PM4:04 pm Corium International announces positive topline results from Phase 1 study of once-weekly transdermal Corplex Donepezil as a potential treatment of Alzheimer's disease -
02/03/16 03:03 PMCorium Announces Positive Topline Results From Phase 1 PK Clinical Study of Once-Weekly Transdermal Corplex™ Donepezil as a Potential Treatment of Alzheimer’s Disease - [GlobeNewswire] - Demonstrates Sustained Delivery, Acceptable Skin Tolerability, and Pharmacokinetic Profile to Support the Feasibility of Once-Weekly Dosing. Webcast and Conference Call Today at 5:00 p.m. ET. MENLO PARK, ...
02/01/16 03:23 PMCorium to Report First Quarter Fiscal Year 2016 Financial Results on Monday, February 8, 2016 - [at noodls] - , (GLOBE NEWSWIRE) -- (NASDAQ:CORI) today announced that it will report financial results for the first fiscal quarter ended on Monday, February 8, 2016 after the close of the financial markets. Corium ...
01/26/16 07:19 AMCorium to Present at LEERINK Partners 5th Annual Global Healthcare Conference - [at noodls] - MENLO PARK, Calif., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization ...
01/22/16 10:04 AMOsteoporosis Therapeutics Pipeline Report, H2 2015 - Research and Markets - Inc. Chronos Therapeutics Limited Chugai Pharmaceutical Co., Ltd. Corium International, Inc. Galapagos NV Glide Pharmaceutical Technologies Limited Hanmi Pharmaceuticals, Co. Ltd. Haoma Medica Ltd. IMMD Inc. Lotus Pharmaceutical Co., Ltd. Lupin Limited ...
12/30/15 03:08 PMCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -
12/24/15 09:48 AMCorium International, Inc. Earnings Analysis: Q4, 2015 By the Numbers -
12/19/15 12:04 PMCORIUM INTERNATIONAL, INC. Financials -
12/16/15 05:07 AMCORIUM INTERNATIONAL, INC. Files SEC form 10-K, Annual Report -
11/30/15 07:20 AMEquities on the Move - Research on Xerium, Mattersight, Corium International and Sears Hometown - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 30, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Xerium Technologies ...
11/12/15 06:15 PMCorium reports 4Q loss -
11/12/15 04:00 PMCorium International Inc Earnings Call scheduled for 5:00 pm ET today -
11/12/15 03:36 PMCorium Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Year-End Highlights - [at noodls] - MENLO PARK, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization ...
11/12/15 03:15 PMCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and -
11/12/15 06:07 AMQ4 2015 Corium International Inc Earnings Release - After Market Close -
11/05/15 07:30 AMCorium to Report Fourth Quarter and Year-End Fiscal Year 2015 Financial Results on Thursday, November 12, 2015 - [at noodls] - Corium to Report Fourth Quarter and Year-End Fiscal Year 2015 Financial Results on Thursday, November 12, 2015
About Corium International

Corium International logoCorium International, Inc. is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules. Its Corplex and MicroCor platforms address the shortcomings of traditional transdermal drug delivery. Its marketed products include Clonidine TDS, which is a treatment for hypertension; Fentanyl TDS, which is a treatment for management of chronic pain, and Crest Whitestrips are a series of five products for oral care. Its Twirla is designed to deliver both hormones at levels comparable to low-dose oral contraceptives. Its MicroCor hPTH(1‑34) is a transdermal system designed to use its MicroCor technology to provide the delivery of parathyroid hormone.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CORI
  • CUSIP:
Key Metrics:
  • Previous Close: $4.06
  • 50 Day Moving Average: $3.86
  • 200 Day Moving Average: $5.05
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $90.49M
  • Current Quarter EPS Consensus Estimate: $-1.70 EPS
Additional Links:
Corium International (NASDAQ:CORI) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha